My Research – Session 4: Risk Predictions – Statistical versus Machine learning methods – Wednesday May 12th at 7pm!

Session 4 (Wednesday 12th May at 19:00 GMT) –  CLICK HERE to REGISTER

 

We would like to invite you to join our monthly ‘My Research’ sessions. These sessions are delivered by members that have undertaken an audit or evaluation. They will spend 10 minutes describing their career pathway and the next 10 minutes about the research methods that they used. There will be time for detailed questions following the talk. These sessions will enable members to learn about quantitative and qualitative methods and the learning may guide and help you in your future projects. We also hope that this will be a good opportunity to learn about different career pathways in cancer pharmacy.

 

The session will be delivered by: Pinkie Chambers and Bruce Burnett

 

Biography (Pinkie Chambers) – Pinkie is a clinical academic at University College London (UCL) and University College NHS Foundation Trust.   Her research activities are all around improving the delivery of systemic anticancer treatments and has experience of using large datasets and prognostic modelling techniques. She has held various roles within cancer including developing new clinic pharmacy services at UCLH and Lead Pharmacist for London Cancer. She the current co-chair of the UK Chemotherapy board , joint audit, and research lead for BOPA and chair of The Chemotherapy Expert Reference group at the NCL cancer alliance as well as a member of the Heath Foundation Q Community.

 

 

 

 

 

Biography (Bruce Burnett) – My name is Bruce Burnett and I am a final year PhD student at Swansea University. I have a Master of Medical Sciences in Clinical Oncology and a Batchelor of Science degree in Pharmacy with a postgraduate certificate in Supplementary Prescribing.  My current research relates to the prediction of colorectal cancer from routinely collected health and social data using machine learning techniques. Previously I was an oncology pharmacist with over 15 years experience and an interest in head and neck and upper GI cancers. I am also a guest lecturer at Coventry University on the topic of biopharmaceuticals in the management of cancer.

 

 

 

 

 

 

 

 

 

Please Note:

-Webinars will start at 19:00 GMT and will last about 30 minutes to 1 hour

-The Zoom link for the webinar will be sent on the day of the event around 17:30pm (if you would like the link before this time please email [email protected])

-Webinars are FREE to access for BOPA Paid Members

-Webinars will be recorded and appear in the BOPA eLearning section of the website via this link: https://www.bopa.org.uk/course-category/audit-and-research/

-Webinars will aim to be on a monthly basis

 

Pinkie, Bastiaan and Alkesh
BOPA Audit & Research and Education &Training Sub-Committee Chairs

 

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article